Catalent (NYSE:CTLT) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a report issued on Sunday morning. The firm issued a sell rating on the stock.

A number of other research firms have also weighed in on CTLT. Barclays upped their price objective on Catalent from $45.00 to $47.00 and gave the stock an equal weight rating in a research report on Thursday, January 25th. Stephens reiterated an equal weight rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. Royal Bank of Canada reiterated a sector perform rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, February 20th. Finally, UBS Group reaffirmed a neutral rating and set a $63.50 price objective (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Catalent presently has an average rating of Hold and an average target price of $52.46.

Catalent Trading Down 0.2 %

Shares of CTLT stock traded down $0.13 on Friday, hitting $56.37. The stock had a trading volume of 1,187,678 shares, compared to its average volume of 2,479,066. The company’s 50 day moving average price is $56.47 and its 200-day moving average price is $49.07. Catalent has a 1 year low of $31.45 and a 1 year high of $60.20. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). The business had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The firm’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same quarter last year, the company earned $0.62 earnings per share. On average, research analysts anticipate that Catalent will post 0.28 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CTLT. Nomura Holdings Inc. raised its holdings in shares of Catalent by 149.4% in the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock worth $516,126,000 after acquiring an additional 6,881,914 shares during the last quarter. Norges Bank purchased a new position in Catalent in the 4th quarter valued at about $116,021,000. Cadian Capital Management LP lifted its stake in shares of Catalent by 91.0% during the third quarter. Cadian Capital Management LP now owns 5,304,784 shares of the company’s stock valued at $241,527,000 after buying an additional 2,526,750 shares during the period. Barclays PLC increased its stake in Catalent by 41.7% in the third quarter. Barclays PLC now owns 4,797,718 shares of the company’s stock valued at $218,440,000 after purchasing an additional 1,412,058 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in Catalent by 65.9% in the third quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock valued at $158,601,000 after purchasing an additional 1,384,313 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.